<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>11(11)</volume><submitter>Fukao Y</submitter><pubmed_abstract>In patients with IgA nephropathy (IgAN), circulatory IgA1 and IgA1 in the mesangial deposits contain galactose-deficient IgA1 (Gd-IgA1). Some of the Gd-IgA1 from the glomerular deposits is excreted in the urine and thus urinary Gd-IgA1 may represent a disease-specific marker. We recruited 338 Japanese biopsy-proven IgAN patients and 120 patients with other renal diseases (disease controls). Urine samples collected at the time of renal biopsy were used to measure Gd-IgA1 levels using a specific monoclonal antibody (KM55 mAb). Urinary Gd-IgA1 levels were significantly higher in patients with IgAN than in disease controls. Moreover, urinary Gd-IgA1 was significantly correlated with the severity of the histopathological parameters in IgAN patients. Next, we validated the use of urinary Gd-IgA1</pubmed_abstract><journal>Journal of clinical medicine</journal><pagination>3173</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9181435</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Galactose-Deficient IgA1 as a Candidate Urinary Marker of IgA Nephropathy.</pubmed_title><pmcid>PMC9181435</pmcid><pubmed_authors>Jeong KH</pubmed_authors><pubmed_authors>Lee M</pubmed_authors><pubmed_authors>Lee SH</pubmed_authors><pubmed_authors>Kato R</pubmed_authors><pubmed_authors>Kano T</pubmed_authors><pubmed_authors>Fukao Y</pubmed_authors><pubmed_authors>Suzuki H</pubmed_authors><pubmed_authors>Kim JS</pubmed_authors><pubmed_authors>Nihei Y</pubmed_authors><pubmed_authors>Makita Y</pubmed_authors><pubmed_authors>Chang JM</pubmed_authors><pubmed_authors>Suzuki Y</pubmed_authors><pubmed_authors>Nakayama M</pubmed_authors></additional><is_claimable>false</is_claimable><name>Galactose-Deficient IgA1 as a Candidate Urinary Marker of IgA Nephropathy.</name><description>In patients with IgA nephropathy (IgAN), circulatory IgA1 and IgA1 in the mesangial deposits contain galactose-deficient IgA1 (Gd-IgA1). Some of the Gd-IgA1 from the glomerular deposits is excreted in the urine and thus urinary Gd-IgA1 may represent a disease-specific marker. We recruited 338 Japanese biopsy-proven IgAN patients and 120 patients with other renal diseases (disease controls). Urine samples collected at the time of renal biopsy were used to measure Gd-IgA1 levels using a specific monoclonal antibody (KM55 mAb). Urinary Gd-IgA1 levels were significantly higher in patients with IgAN than in disease controls. Moreover, urinary Gd-IgA1 was significantly correlated with the severity of the histopathological parameters in IgAN patients. Next, we validated the use of urinary Gd-IgA1</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Jun</publication><modification>2025-05-29T21:21:20.89Z</modification><creation>2025-02-19T03:51:57.267Z</creation></dates><accession>S-EPMC9181435</accession><cross_references><pubmed>35683557</pubmed><doi>10.3390/jcm11113173</doi></cross_references></HashMap>